IPW

In re the Application of: Shigetoshi KADOTA et al.

Group Art Unit: 1615

Serial Number: 10/522,186

Filed: January 24, 2005 Confirmation No.: 3671

For: HYPOGLYCEMIC AGENT, LIVER PROTECTING AGENT AND

ANTICANCER AGENT CONTAINING LIGNANS ORIGINATING IN HONGDOUSHAN

Attorney Docket Number: 043157
Customer Number: 38834

# REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop: Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

November 7, 2005

Sir:

Please supply the undersigned attorney with a corrected filing receipt for the above-identified application. The undersigned also respectfully requests that the Patent and Trademark Office records be amended to reflect the correction.

In reviewing the Official Filing Receipt, we noted the <u>Assignee's Information</u> was not recorded. The Assignee's Information should read --KOTOSUGI INC., Sagamihara-shi, JAPAN--. A copy of the Transmittal Letter is enclosed which indicates the correct information. We are also enclosing a copy of the filing receipt with the corrections highlighted.

Request for Corrected Filing Receipt 10/522,186 043157

If any fees are required in connection with this paper, please charge Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DAMIELS & ADRIAN, LLP

Stephen G. Adrian
Attorney for Applicants
Registration No. 32,878
Telephone: (202) 822-1100

Facsimile: (202) 822-1111

SGA/if

Enclosures: Official Filing Receipt; Transmittal Letter



38834

SUITE 700

Jnited States RADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING OR 371 APPL NO. ART UNIT FIL FEE REC'D DOCKET NO DRAWINGS TOT CLMS IND CLMS (c) DATE 10/522,186 01/24/2005 1615 1100 043157 6 8 OCT 14

2005

**CONFIRMATION NO. 3671** 

FILING RECEIPT

OC000000017145879\*

Date Mailed: 10/11/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check-or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Shigetoshi Kadota, Toyama, JAPAN; Takahiro Nobukawa, Kanagawa, JAPAN; Assignment for Published Pateral Application

KOTOSWEIL LINC, Sagamiharosski, JAPANSSKI Power of Attorney: The patent practitioners associated with Customer Number 38834.

Domestic Priority data as claimed by applicant

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP

1250 CONNECTICUT AVENUE, NW

WASHINGTON, DC 20036

This application is a 371 of PCT/JP03/09370 07/23/2003

Foreign Applications

JAPAN 2002-214694 07/24/2002 JAPAN 2003-119178 04/24/2003

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in

hongdoushan

**Preliminary Class** 

514

### PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

5

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE			DATE: January 24, 2005	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application. No. (if known):		
INTERNATIONAL APPLICATION NO.: PCT/JP2003/09370		INTERNATIONAL FILING DATE: July 23, 2003	PRIORITY DATE CLAIMENOV 0 7 2005	
TITLE OF INVENTION: HYPOGLYCEMIC AGENT, HEPATOPROTECTING AGENT AND ANTICANCER AGENT LIGNANS DERIVED FROM HONGDOUSHAN				
APPLICANT(S) FOR DO/EO/US: Shigetoshi KADOTA and Takahiro NOBUKAWA				
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
1. <u>XX</u>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <u>XX</u>	This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.			
4. <u>XX</u>	The US has been elected (Article 31).			
5. <u>XX</u>	A copy of the International Application as filed (35 U.S.C. 371(c)(2)):  a. is transmitted herewith (required only if not transmitted by the International Bureau).  b. XX has been transmitted by the International Bureau.  c. is not required, as the application was filed in the United States Receiving Office (RO/US)			
6. <u>XX</u>	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).  a. XX is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4).			
7. <u>XX</u>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  a. are transmitted herewith (required only if not transmitted by the International Bureau).  b. have been transmitted by the International Bureau.  c. have not been made; however, the time limit for making such amendments has NOT expired.  d. XX have not been made and will not be made.			
8	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. <u>XX</u>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
ITEMS 11. TO 20. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:				
11. XX An Information Disclosure Statement under 37 CFR 1.97 and 1.98 together with the international search report, PTO-1449.				
12. XX An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.  ASSIGNEE NAME AND ADDRESS: KOTOSUGITINE; Sagamihara-shi; Japan  Please publish the assignee data with the application.				
13 A preliminary amendment.				
14	An Application Data Sheet under 37 C.F.R. 1.76			
15 A substitute specification.				
16 A change of power of attorney and/or address letter.				
17	17 A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825.			
18	A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19 A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				
20. XX	0. XX Other items or information: 6 sheets of drawings.			